Skip to content

Metabolic fate of drugs of abuse and new psychoactive substances: A pilot study on a novel workflow using a zebrafish embryo model combined with human microdosing.

Wellenberg K Simon, Tanja M Gampfer, Wagmann Lea, Schippers Philip, Herrmann Jennifer, Müller Rolf, Westphal Folker, Markus R Meyer

British Journal of Clinical Pharmacology June 16, 2025 DOI: 10.1002/bcp.70140 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Experimental study with zebrafish embryo model and human microdosing Pilot study Peer reviewed
Population Zebrafish embryos and human participants
Interventions Amphetamine cocaine LSD MDMA methamphetamine THC MDMB-CHMICA MDPPP
Duration 24 h
Topics Microdosing
Keywords Lc‐hrms/ms Drugs of abuse New psychoactive substances Xenobiotic metabolism Animal model Drug analysis Toxicology screening Zebrafish model zebrafish Zebrafish embryos Research model Biological model Drug metabolism metabolism Drug pharmacokinetics Metabolite identification Biomarker discovery Substance identification Drug testing Lc-hrms/ms
Citations 1
Key findings Zebrafish embryo metabolism followed by human microdosing can identify main human urine metabolites for drugs of abuse, though challenges with low doses and bioavailability remain.

Abstract

The aim of this study was to develop a novel workflow to identify human urine biomarkers for drugs of abuse and new psychoactive substances. Metabolites of amphetamine, cocaine, LSD, MDMA, methamphetamine, THC, MDMB-CHMICA, and MDPPP were first identified in a zebrafish embryo (ZE) metabolism study followed by comparison to most abundant human metabolites in literature. Finally, metabolites were confirmed by human microdosing (HMD). ZEs 4 days post fertilization were exposed via immersion in Danieau's medium containing the compound or by injection into the caudal vein. After euthanization and freeze-drying, the ZEs were extracted using methanol. HMD was performed by oral administration of individual compound solutions according to HMD guidelines. Urine was collected spontaneously over 24 h and extracted via solid-phase extraction with and without conjugate cleavage. Samples were then analysed using reversed-phase liquid chromatography coupled to high resolution tandem mass spectrometry. Overall, both ZE and HMD allowed identification of main human urine metabolites as described in literature. Exceptions for HMD were LSD due to the low applied dose and the cannabinoids, probably due to low oral bioavailability. Furthermore, ZE generally produced more metabolites compared to HMD, including conjugates. The proposed workflow of ZE exposure followed by HMD can provide quick and reliable data for prediction of analytical biomarkers for urinary drug screening. Following the initial identification of metabolites in ZE, human metabolites can afterwards be confirmed by HMD study. However, there are still challenges regarding HMD such as different routes of administration and detectability of applied low doses.

Comparable studies

Other preclinical and animal studies on microdosing, most cited first.

Study Year Design Participants
Psilocin and ketamine microdosing: effects of subchronic intermittent microdoses in the elevated plus-maze in male Wistar rats Wistar rats 2018 Experimental study n = 40
Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats. Rats 2023 Experimental study
Repeated microdoses of LSD do not alter anxiety or boldness in zebrafish. Zebrafish (Danio rerio) 2024 Experimental study
Application of microarray patches for the transdermal administration of psychedelic drugs in micro-doses. Excised neonatal porcine skin and rats 2025 Experimental study
Toward Predicting Acute Myeloid Leukemia Patient Response to 7 + 3 Induction Chemotherapy via Diagnostic Microdosing Paired sensitive and resistant cancer cell lines, AML cell lines, and 10 viably... 2018 Preclinical cell line study with a pilot retrospective analysis of primary patient samples n = 10

Citations in the library

Explore topics